Predicting the Clinical Outcome of Triple-Negative Breast Cancer Based on the Gene Expression Characteristics of Necroptosis and Different Molecular Subtypes

<div>Immunotherapy/chemotherapy difference between the two subtypes in the RNAseq data set. (a) Immune checkpoints present differential expression between the various groups in the RNAseq data set. (b) The TIDE analysis difference between different groups in the RNAseq queue. (c) The box plots constructed using the calculated IC50 for sunitinib, paclitaxel, crizotinib, and bexarotene in RNAseq.</div>

Stem Cells International

fig3

Figure 3

Figure 3: Predicting the Clinical Outcome of Triple-Negative Breast Cancer Based on the Gene Expression Characteristics of Necroptosis and Different Molecular Subtypes 

Figure 3 | Predicting the Clinical Outcome of Triple-Negative Breast Cancer Based on the Gene Expression Characteristics of Necroptosis and Different Molecular Subtypes 